Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant’s Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with […]

Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences

NEW YORK and TOKYO October 2, 2022 — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction  with parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), announced today it has  submitted a non-binding proposal (the “Proposal”) to the Audit Committee of the Board of Directors  (the “Audit Committee”) of Myovant Sciences Ltd. (“Myovant”) offering to acquire all outstanding […]

Sumitovant Biopharma and its Portfolio of Companies Announce Milestone Highlights from the Third Quarter of FY2021

Sumitomo Dainippon Pharma and Sumitovant announced the launch of a phase 1 study of a new drug candidate for carbapenem-resistant bacterial infections. Two publications on Urovant’s FDA-approved OAB therapy, GEMTESA® (vibegron), showed clinical effectiveness and safety in patients with overactive bladder (OAB). Spirovant presented data on an investigational novel recombinant adeno-associated virus gene therapy at […]

Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant

CAMBRIDGE, Mass. & BASEL, Switzerland, March 2, 2022 – Sumitovant Biopharma and wholly-owned subsidiary Enzyvant, a biopharmaceutical company focused on developing transformative regenerative therapies for patients with rare diseases, today announced the appointment of Bill Symonds, Pharm.D., as interim chief executive officer, effective March 11, 2022. Dr. Symonds has served as the chief executive officer of […]

Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections

Compound inhibits enzymes produced by bacteria that degrade carbapenem antibiotics  LONDON and NEW YORK, February 10, 2022 — Sumitovant Biopharma Ltd., in partnership with its parent company Sumitomo Dainippon Pharma Co., Ltd., recently announced the launch of a phase 1 study in the U.S. on a new drug candidate (“KSP-1007”) for carbapenem-resistant bacterial infections. The […]

Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021

Enzyvant, a wholly-owned subsidiary of Sumitovant, received FDA approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia Myovant, a publicly listed company that is majority-owned by Sumitovant, and its partner Pfizer received FDA acceptance of its supplemental New Drug Application (sNDA) for MYFEMBREE® Urovant, a wholly-owned subsidiary of Sumitovant, […]

Sumitovant Biopharma Highlights Strong First Fiscal Quarter of 2021 with Significant Commercial and Clinical Achievements Across its Portfolio of Companies

Urovant,a wholly-owned subsidiary of Sumitovant, announced commercial availability of GEMTESA® (vibegron) to treat overactive bladder Myovant, a publicly-listed company that is majority-owned by Sumitovant, and its partner, Pfizer, announced the Food and Drug Administration (FDA) approval of MYFEMBREE® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for women with uterine fibroids in premenopausal women […]

Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies

Urovant became a wholly owned subsidiary of Sumitovant and announced the continuation of its Phase 2a study with novel gene therapy, URO-902 in OAB and urinary incontinence Myovant, a publicly listed company that is majority owned by Sumitovant, made key executive appointments and announced product and pipeline accomplishments including the commercial availability of its first […]

Sumitovant Biopharma’s Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of Operation

Third quarter achievements include two FDA approvals and commercialization agreements in prostate cancer and women’s health  LONDON and NEW YORK, March 2, 2021 /GLOBE Newswire/ — Sumitovant Biopharma. today announced that its five subsidiary healthcare companies (Myovant, Urovant, Enzyvant, Altavant and Spirovant ) achieved multiple clinical and corporate milestones in the company’s third quarter ending on December 31, 2020.  “The Sumitovant family of companies continue to advance our pipeline with two […]

Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis

84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year  Data to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021 NEW YORK, LONDON, January 26, 2021  (GLOBE NEWSWIRE) — Sumitovant Biopharma Ltd., a majority shareholder of Myovant […]